Taken together, these observations provide strong rationale for the clinical translation of personalized cancer vaccines.
These findings provide strong rationale for the study of ACE inhibitors and vitamin D replenishment as preventive therapies in this high-risk population.
These results demonstrate that treatment with a soluble form of ActRIIA (ACE-011) enhances bone mass and bone strength in cynomolgus monkeys, and provide strong rationale for exploring the use of ACE-011 to prevent and/or treat skeletal fragility.
These factors provide strong rationale for quality improvement initiatives in CKD care.
Our results provide strong rationale for extensive clinical validation of the association and standardization of test conditions.
Collectively, these findings provide strong rationale for the development of a therapeutic strategy aimed at preventing the hyperphosphorylation of tau on the KXGS motifs.
These experimental approaches provide strong rationale for placebo-controlled pharmacological trials to establish the efficacy of cilostazol in patients with AD/CAA.
Our data certainly provide strong rationale for future studies to mechanistically define the interaction between HCC and the underlying liver fibrosis in recurrence.
Taken together these findings provide strong rationale for anti-invasive therapies targeting CTGF, as this molecule was found to be significantly over-expressed in invasive glioma cells where knock-down studies confirmed biological activity.
As observed in the CTEP/NCI review process of early clinical trial proposals, robust preclinical data generally provide strong rationale and are considered to be of high priority for clinical evaluation.
